Cure8 research brief
This study suggests commonly used GLP-1 receptor agonists (semaglutide, liraglutide) were associated with higher symptomatic and endoscopic remission in ulcerative colitis compared with matched controls. If validated, GLP-1 RAs could offer an adjunctive option for people with UC who also have metabolic comorbidities.
Adults with ulcerative colitis (especially those with metabolic comorbidities), gastroenterologists, clinicians managing metabolic disease, and researchers studying drug repurposing for IBD.
This retrospective matched cohort study (electronic health records, single tertiary center, 2022–2024) found that adults with ulcerative colitis who started GLP-1 receptor agonists (liraglutide or semaglutide) and stayed on therapy ≥12 weeks had higher symptomatic remission at 4, 8, and 12 weeks versus matched UC controls.
Semaglutide showed a modestly higher remission rate than liraglutide. A subset with endoscopic data also showed greater endoscopic remission and improvement in the GLP-1 RA group. Weight loss did not explain the association reported.
These results suggest GLP-1 RAs might have an adjunctive benefit for UC disease activity, especially in patients treated for metabolic indications, but the study is retrospective and from a single center. Randomized trials would be needed to confirm causality and safety specifically for UC.
If you are a patient considering GLP-1 RA therapy, discuss potential benefits and risks with your gastroenterologist and prescribing clinician; do not change or start medications based on this report alone.
This is a retrospective, observational cohort from one academic health system; such designs can show associations but cannot prove causation. The authors report a matched control group and multivariable adjustment, but randomized controlled trials are needed to confirm efficacy and safety for UC specifically.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...
This review pools available pediatric data showing ustekinumab can induce and maintain remission after anti‑TNF failure, offering a treatment option for children with refractory IBD. Results are most robust for Crohn’s...
The article reports regulatory approvals and clinical-trial results for Omvoh (mirikizumab), which could offer a new option for people with moderate–severe Crohn’s who still have disruptive symptoms like bowel urgency....
